Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model

Current Eye Research

Volumn 29, Issue 2-3, 2004, Pages 167-172

  Cullinan, Amy E ^a   Lindstrom, Mary J ^a,b   Sabet, Sina ^a   Albert, Daniel M ^a,b   Brandt, Curtis R ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Herpes simplex virus; LH TAg mouse; Retinoblastoma; Ribonucleotide reductase

Indexed keywords

CARBOPLATIN; ETOPOFOS; ONCOLYTIC VIRUS; RIBONUCLEOTIDE REDUCTASE; VINCRISTINE SULFATE; VIRUS LARGE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; EYE TUMOR; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS RE6; HRR3 VIRUS; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR VIRUS ADMINISTRATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINOBLASTOMA; STAINING; TRANSGENIC MOUSE; TUMOR VOLUME; VIROGENESIS; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS TITRATION;

ANIMALS; CERCOPITHECUS AETHIOPS; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MUTATION; RETINAL NEOPLASMS; RETINOBLASTOMA; RIBONUCLEOTIDE REDUCTASES; SIMPLEXVIRUS; VERO CELLS; VIRUS REPLICATION; VIRUSES;

EID: 9344255529     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680490504894     Document Type: Conference Paper

References (41)

1. Shields C, Shields J. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus. 1999;36:8-18.
2. Shields CL, Shields JA, De Potter P. New treatment modalities for retinoblastoma. Curr Opin Ophthalmol. 1996;7:20-26.
3. Chan H, Thomer P, Haddad G, Gallic B. Multidrug resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology. 1991;98:1425-1431.
4. Kingston J, Hungerford J, Madreperla S, Plowman P. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1339-1343.
5. Murphree AL, Villablanca JG, Deegan WF, Salo JK, Malogolowkin M, Fisher A, Parker R, Reed E, Gomer CJ. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1348-1356.
6. Gallie B, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z, Ling P, Chan HS. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114:1321-1328.
7. Schueler A, Jurklies C, Heimann H, Wieland R, Havers W, Bornfeld N. Thermochemistry in hereditary retinoblastoma. Br J Ophthalmol. 2003;87:90-95.
8. Grostern RJ, Bryar P, Zimbric M, Soesiawati D, Lissauer B, Lindstrom M, Lokken J, Strugnell S, Albert DM. Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograf t model. Arch Ophthalmol. 2002;120:607-612.
9. Sabet S, Djaratmoko S, Lindstrom M, Albert DM. Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D in athymic mice with Y79 human retinoblastoma tumors. Arch Ophthalmol. 1999;117:365-370.
10. Shternfeld IS, Lasudry JG, Chappell RJ, Darjatmoko SR, Albert DM. Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. Arch Ophthalmol. 1996;114:1396-1401.
11. Wilkerson C, Darjatmoko S, Lindstrom M, Albert DM. Toxicity and dose response studies of 1,25(OH)2-16ene-23yne vitamin D3 in transgenic mice. Clin Cancer Res. 1998;4:2253-2256.
12. Brandt C, Imesch P, Robinson N, Syed S, Untawale S, Darjatmoko S, Chappell R, Heinzelman P, Albert DM. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virology. 1997a;229:283-291.
13. Kogishi J, Miyatake S, Hangai M, Akimoto M, Okazaki K, Honda Y. Mutant herpes simplex virus-mediated suppression of retinoblastoma. Curr Eye Res. 1999;18:321-326.
14. Nicolo M, Chiocca E. Marker gene transfer and oncolysis of human Y79 retinoblastoma cells mediated by herpes simplex virus mutants. Ophthalmic Res. 1997;30:30-36.
15. Hurwitz M, Marcus K, Chevez-Barrios P, Louie K, Aguilar-Cordova E, Hurwitz RL. Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther. 1999;10:441-448.
16. Markert JM, Gillespie GY, Weichselbaum RR, Roadman B, Whitley RJ. Genetically engineered HSV in the treatment of glioma: A review. Rev Med Virol. 2000;10:17-30.
17. Burton E, Wechuck J, Wendell S, Goins W, Fink D, Glorioso J. Multiple applications for replication-defective Herpes simplex virus vectors. Stem Cells. 2001;19:358-377.
18. Mineta T, Rabkin S, Martuza RL. Treatment of malignant gliomas using gancyclovir-hypersensitive, ribonucleotide reductase-deficient Herpes simplex viral mutants. Cancer Res. 1994;54:3963-3966.
19. Macleod KF, Jacks T. Insights into cancer from transgenic mouse models. J Pathol. 1999;187:43-60.
20. Windle J, Albert DM, O'Brien J, Marcus DM, Disteche CM, Bernards R, Mellon PL. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
21. O'Brien J, Marcus D, Bernards R, Carpenter J, Windle J, Mellon PD, Albert D. A transgenic model for trilateral retinoblastoma. Arch Ophthalomol. 1990;108:1145-1151.
22. Albert DM, Marcus D, Gallo J, O'Brien J. The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Invest Ophthalmol Vis Sci. 1992;33:2343-2364.
23. Cameron JM, McDougall I, Marsden HS, Preston VG, Ryan DM, Subak-Sharpe JH. Ribonucleotide reductase encoded by Herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol. 1988;69:2607-2612.
24. Jacobson J, Leib D, Goldstein D, Bogard C, Schaffer P, Weller S, Coen D. A Herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology. 1989;173:276-283.
25. Brandt CR, Kintner RL, Pumfery AM, Visalli RJ, Grau DR. The Herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol. 1991;72:2043-2049.
26. Brandt CR, Imesch P, Spencer B, Eliassi-Rad B, Untawale S, Robinson N, Albert D. The Herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease. Arch Virol. 1997b;142:883-896.
27. Goldstein D, Weller SK. Factor(s) present in Herpes simplex virus type-1 infected cells can compensate for the loss of the large subunit of the viral ribonulceotide reductase: Characterization of an ICP6 deletion mutant. Virology. 1988;166:41-51.
28. Grau DR, Visalli RJ, Brandt CR. Herpes simplex virus stromal keratitis is not titer-dependent and does not correlate with neurovirulence. Invest Ophthalmol Vis Sci. 1989;30:2474-2480.
29. Thompson RL, Wagner EK, Stevens JG. Physical location of a Herpes simplex virus type-1 gene function(s) specifically associated with a 10 million-fold increase in HSV neurovirulence. Virology. 1983;131:180-192.
30. Spencer B, Agarwala S, Gentry L, Brandt CR. HSV-1 vector-delivered FGF2 to the retina is neuroprotective, but does not preserve functional responses. Mol Ther. 2001;3:746-756.
31. Brandt C, Grau D. Mixed infection with herpes simplex virus Type 1 generates recombinants with increased ocular and neurovirulence. Invest Ophthalmol Vis Sci. 1990;31:2214-2223.
32. Boviatsis E, Scharf J, Chase M, Harrington K, Kowall N, Breakefield XO, Chiocca EA. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with Herpes simplex virus vectors defective in thymidine kinase and ribonucleotide reductase. Gene Ther. 1994;1:323-331.
33. Kramm C, Chase M, Herrlinger U, Jacobs A, Pechan P, Rainov N, Sena-Esteves M, Aghi M, Chiocca EA, Breakefield XO. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther. 1997;8:2057-2068.
34. Kayusa H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A. Intraperitoneal delivery of hrR3 and gancyclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol. 1999;72:136-141.
35. Yoon S, Nakamura H, Carroll N, Bode B, Chiocca EA, Tanabe K. An oncolytic Herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 2000;14:301-311.
36. Howes K, Lausdry J, Albert D, Windle J. Photoreceptor tumors in transgenic mice. Invest Ophthalmol Vis Sci. 1994;35:342-351.
37. Mills M, Windle J, Albert DM. Retinoblastoma in transgenic mice: Models of hereditary retinoblastoma. Surv Ophthalmol. 1999;43:508-518.
38. Ferris F, Chew E. A new era for the treatment of retinoblastoma. Arch Ophthalmol. 1996;114:1412.
39. Brandt CR, Kintner R, Pumfery A, Visalli RJ, Grau DR. The Herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol. 1991;72:2043-2049.
40. 134.5 deletion mutants in rodent models. J Clin Invest. 1993;91:2387-2843.
41. Bolovan CA, Sawtell N, Thompson RL. ICP34.5 mutants of herpes simplex virus Type-I strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cultures. J Virol. 1994;68:48-55.